Provided by Tiger Fintech (Singapore) Pte. Ltd.

Glaukos

105.29
-6.8300-6.09%
Volume:389.26K
Turnover:41.98M
Market Cap:5.95B
PE:-37.95
High:110.22
Open:109.22
Low:105.29
Close:112.12
Loading ...

Glaukos Q3 Non-GAAP Loss Narrows, Sales Increase; 2024 Sales Guidance Raised

MT Newswires Live
·
05 Nov 2024

Stock Track | Glaukos Stock Plunges After-Hours Despite Q3 Revenue Beat

Stock Track
·
05 Nov 2024

Glaukos: Q3 Earnings Snapshot

Associated Press Finance
·
05 Nov 2024

Glaukos Q3 2024 Adj. EPS $(0.28) Beats $(0.48) Estimate, Sales $96.700M Beat $91.494M Estimate

Benzinga
·
05 Nov 2024

Glaukos Corp: Raised 2024 Net Sales Guidance to $377 Mln to $379 Mln

THOMSON REUTERS
·
05 Nov 2024

Glaukos Announces Third Quarter 2024 Financial Results

Business Wire
·
05 Nov 2024

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
04 Nov 2024

Possible Bearish Signals With Glaukos Insiders Disposing Stock

Simply Wall St.
·
31 Oct 2024

Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks
·
28 Oct 2024

Analysts Conflicted on These Healthcare Names: Medpace Holdings (MEDP), McKesson (MCK) and Glaukos (GKOS)

TIPRANKS
·
22 Oct 2024

Glaukos iDose: Transforming Glaucoma Treatment with Promising Growth Potential

TIPRANKS
·
21 Oct 2024

GKOS Stock Rises on Positive Phase 3 Confirmatory Trial for Epioxa

Zacks
·
17 Oct 2024

Stifel Nicolaus Issues a Buy Rating on Glaukos (GKOS)

TIPRANKS
·
17 Oct 2024

Glaukos Reports Positive Results From Potential Eye Disease Treatment Study

MT Newswires Live
·
17 Oct 2024

BRIEF-Glaukos Announces Positive Topline Outcomes In Phase 3 Confirmatory Trial For Epioxa, Achieving Primary Efficacy Endpoint And Demonstrating Favorable Tolerability And Safety

Reuters
·
17 Oct 2024

Glaukos says Epioxa Phase 3 confirmatory trial meets primary endpoint

TIPRANKS
·
17 Oct 2024